Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 7 (July)

1. Infections during induction therapy for children with acute lymphoblastic leukemia. the role of sulfamethoxazole-trimethoprim (SMX-TMP) prophylaxis.
   Pediatr Blood Cancer, 55(2): 304-8. [Abstract] [Full-text]
2. Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
   Pediatr Blood Cancer, 55(2): 239-47. [Abstract] [Full-text]
3. Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy.
   Pediatr Blood Cancer, 55(2): 386-9. [Abstract] [Full-text]
4. Placing of tunneled central venous catheters prior to induction chemotherapy in children with acute lymphoblastic leukemia.
   Pediatr Blood Cancer, 55(2): 309-13. [Abstract] [Full-text]
5. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
   Pediatr Blood Cancer, 55(2): 254-9. [Abstract] [Full-text]
6. How to manage an unresectable or recurrent sialoblastoma.
   Pediatr Blood Cancer, 55(2): 374-6. [Abstract] [Full-text]
7. Methicillin-resistant Staphylococcus aureus infection in septorhinoplasty.
   Laryngoscope, 120(7): 1309-11. [Abstract] [Full-text]
8. Methadone-induced rigid-chest syndrome after substantial overdose.
   Pediatrics, 126(1): e232-4. [Abstract] [Full-text]
9. Prior use of antimicrobial therapy is a risk factor for culture-negative prosthetic joint infection.
   Clin Orthop Relat Res, 468(8): 2039-45. [Abstract] [Full-text]
10. An Approach for determining antibiotic loading for a physician-directed antibiotic-loaded PMMA bone cement formulation.
    Clin Orthop Relat Res, 468(8): 2092-100. [Abstract] [Full-text]
11. Performance and training standards for endovascular ischemic stroke treatment.
    J Neurosurg, 113(1): 149-52. [Abstract] [Full-text]
12. Ventricular enlargement due to acute hypernatremia in a patient with a ventriculoperitoneal shunt.
    J Neurosurg, 113(1): 82-4. [Abstract] [Full-text]
13. Short course combination therapy for giardiasis after nitroimidazole failure.
    Am J Trop Med Hyg, 83(1): 171-3. [Abstract] [Full-text]
14. Adrenal function status in patients with paracoccidioidomycosis after prolonged post-therapy follow-up.
    Am J Trop Med Hyg, 83(1): 111-4. [Abstract] [Full-text]
15. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.
    Am J Trop Med Hyg, 83(1): 97-101. [Abstract] [Full-text]
16. Dynamics of Plasmodium falciparum parasitemia regarding combined treatment regimens for acute uncomplicated malaria, Antioquia, Colombia.
    Am J Trop Med Hyg, 83(1): 90-6. [Abstract] [Full-text]
17. Peptides derived from specific interaction sites of the fibroblast growth factor 2-FGF receptor complexes induce receptor activation and signaling.
    J Neurochem, 114(1): 74-86. [Abstract] [Full-text]
18. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    J Immunol, 185(2): 956-66. [Abstract] [Full-text]
19. The benefits and challenges associated with the use of drug delivery systems in cancer therapy.
    Biochem Pharmacol, 80(5): 762-70. [Abstract] [Full-text]
20. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".
    Biochem Pharmacol, 80(5): 666-73. [Abstract] [Full-text]
21. Controlled hypotension in patients suspected of a ruptured abdominal aortic aneurysm: feasibility during transport by ambulance services and possible harm.
    Eur J Vasc Endovasc Surg, 40(1): 54-9. [Abstract] [Full-text]
22. Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging.
    Philos Transact A Math Phys Eng Sci, 368(1924): 3683-712. [Abstract] [Full-text]
23. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial.
    J Natl Cancer Inst, 102(13): 982-7. [Abstract] [Full-text]
24. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.
    Strahlenther Onkol, 186(7): 374-81. [Abstract] [Full-text]
25. Combined-modality treatment for anal cancer: current strategies and future directions.
    Strahlenther Onkol, 186(7): 361-6. [Abstract] [Full-text]
26. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.
    Br J Ophthalmol, 94(7): 864-70. [Abstract] [Full-text]
27. Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
    J Pediatr Hematol Oncol, 32(5): e202-6. [Abstract] [Full-text]
28. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy.
    J Pediatr Hematol Oncol, 32(5): e182-6. [Abstract] [Full-text]
29. Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol.
    J Pediatr Hematol Oncol, 32(5): 370-5. [Abstract] [Full-text]
30. Progress and barriers for the control of diarrhoeal disease.
    Lancet, 376(9734): 63-7. [Abstract] [Full-text]
31. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Am J Ophthalmol, 150(1): 48-54.e1. [Abstract] [Full-text]
32. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Lancet Oncol, 11(7): 619-26. [Abstract] [Full-text]
33. Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1).
    Gynecol Oncol, 118(2): 128-33. [Abstract] [Full-text]
34. Lipoatrophy induced by subcutaneous insulin infusion: ultrastructural analysis and gene expression profiling.
    J Clin Endocrinol Metab, 95(7): 3126-32. [Abstract] [Full-text]
35. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Gynecol Oncol, 118(2): 139-44. [Abstract] [Full-text]
36. Targeted therapies for rare gynaecological cancers.
    Lancet Oncol, 11(7): 685-93. [Abstract] [Full-text]
37. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
    Lancet Oncol, 11(7): 670-8. [Abstract] [Full-text]
38. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
    Ophthalmology, 117(7): 1393-9.e3. [Abstract] [Full-text]
39. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
    Int J Radiat Oncol Biol Phys, 77(4): 1105-12. [Abstract] [Full-text]
40. Interventions for replacing missing teeth: antibiotics at dental implant placement to prevent complications.
    Cochrane Database Syst Rev, 7: CD004152. [Abstract] [Full-text]
41. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis.
    Lancet Infect Dis, 10(7): 464-9. [Abstract] [Full-text]
42. Measurement of corneal changes after collagen crosslinking using a noninvasive ultrasound system.
    J Cataract Refract Surg, 36(7): 1207-12. [Abstract] [Full-text]
43. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.
    Anticancer Drugs, 21(7): 716-23. [Abstract] [Full-text]
44. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
    Anticancer Drugs, 21(7): 669-73. [Abstract] [Full-text]
45. Bevacizumab improves the delivery and efficacy of paclitaxel.
    Anticancer Drugs, 21(7): 687-94. [Abstract] [Full-text]
46. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries.
    J Acquir Immune Defic Syndr, 54(4): 437-41. [Abstract] [Full-text]
47. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
    J Clin Oncol, 28(20): 3284-91. [Abstract] [Full-text]
48. Emerging targeted therapies for breast cancer.
    J Clin Oncol, 28(20): 3366-79. [Abstract] [Full-text]
49. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
    J Clin Oncol, 28(20): 3227-33. [Abstract] [Full-text]
50. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    J Clin Oncol, 28(20): 3299-306. [Abstract] [Full-text]
51. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    J Clin Oncol, 28(20): 3256-63. [Abstract] [Full-text]
52. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
    J Clin Oncol, 28(20): 3248-55. [Abstract] [Full-text]
53. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
    J Clin Oncol, 28(20): 3360-5. [Abstract] [Full-text]
54. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    J Clin Oncol, 28(20): 3239-47. [Abstract] [Full-text]
55. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    J Clin Oncol, 28(20): 3323-9. [Abstract] [Full-text]
56. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
    J Clin Oncol, 28(20): 3336-43. [Abstract] [Full-text]
57. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends.
    Eur J Surg Oncol, 36(7): 599-603. [Abstract] [Full-text]
58. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005.
    Am J Public Health, 100(8): 1493-9. [Abstract] [Full-text]
59. Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells.
    Otolaryngol Head Neck Surg, 143(1): 109-15. [Abstract] [Full-text]
60. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
    J Biol Chem, 285(29): 22639-50. [Abstract] [Full-text]
61. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides.
    J Biol Chem, 285(29): 22532-41. [Abstract] [Full-text]
62. Aggressive treatment of idiopathic axillo-subclavian vein thrombosis provides excellent long-term function.
    J Vasc Surg, 52(1): 127-31. [Abstract] [Full-text]
63. A statewide prescription monitoring program affects emergency department prescribing behaviors.
    Ann Emerg Med, 56(1): 19-23.e1-3. [Abstract] [Full-text]
64. Characterization of and biomolecule immobilization on the biocompatible multi-walled carbon nanotubes generated by functionalization with polyamidoamine dendrimers.
    Colloids Surf B Biointerfaces, 80(1): 18-25. [Abstract] [Full-text]
65. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.
    Trop Med Int Health, 15(7): 825-32. [Abstract] [Full-text]
66. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
    Br J Cancer, 103(2): 201-8. [Abstract] [Full-text]
67. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.
    Br J Cancer, 103(2): 232-8. [Abstract] [Full-text]
68. From medical rationing to rationalizing the use of human resources for AIDS care and treatment in Africa: a case for task shifting.
    Dev World Bioeth, 10(2): 99-103. [Abstract] [Full-text]
69. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    J Infect Dis, 202(4): 585-94. [Abstract] [Full-text]
70. Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit.
    Eur J Surg Oncol, 36(7): 610-6. [Abstract] [Full-text]
71. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Cancer Chemother Pharmacol, 66(4): 721-8. [Abstract] [Full-text]
72. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Cancer Chemother Pharmacol, 66(4): 659-67. [Abstract] [Full-text]
73. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Cancer Chemother Pharmacol, 66(4): 729-36. [Abstract] [Full-text]
74. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
    Invest New Drugs, 28(5): 659-69. [Abstract] [Full-text]
75. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
    Invest New Drugs, 28(5): 634-40. [Abstract] [Full-text]
76. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy.
    J Am Acad Dermatol, 63(2): 195-211; quiz 211-2. [Abstract] [Full-text]
77. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part I. Acne vulgaris: when and why consider photodynamic therapy?
    J Am Acad Dermatol, 63(2): 183-93; quiz 193-4. [Abstract] [Full-text]
78. Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses.
    J Am Acad Dermatol, 63(2): 213-8. [Abstract] [Full-text]
79. Permanent chemotherapy-induced alopecia: case report and review of the literature.
    J Am Acad Dermatol, 63(2): 333-6. [Abstract] [Full-text]
80. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
    Blood, 116(2): 250-3. [Abstract] [Full-text]
81. Does immediate breast reconstruction using free flaps lead to delay in the administration of adjuvant chemotherapy for breast cancer?
    Eur J Surg Oncol, 36(8): 745-9. [Abstract] [Full-text]
82. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
    Eur J Surg Oncol, 36(8): 772-6. [Abstract] [Full-text]
83. Gastric cancer in the elderly: an overview.
    Eur J Surg Oncol, 36(8): 709-17. [Abstract] [Full-text]
84. Are 2 smaller intravenous catheters as good as 1 larger intravenous catheter?
    Am J Emerg Med, 28(6): 724-7. [Abstract] [Full-text]
85. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters.
    J Thorac Cardiovasc Surg, 140(2): 471-5. [Abstract] [Full-text]
86. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.
    J Clin Oncol, 28(21): 3516-24. [Abstract] [Full-text]
87. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
    J Clin Oncol, 28(21): 3463-71. [Abstract] [Full-text]
88. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
    J Clin Oncol, 28(21): 3416-21. [Abstract] [Full-text]
89. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
    J Clin Oncol, 28(21): 3491-7. [Abstract] [Full-text]
90. Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy.
    J Virol, 84(16): 8348-52. [Abstract] [Full-text]
91. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
    J Thorac Cardiovasc Surg, 140(2): 356-63. [Abstract] [Full-text]
92. Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma.
    Int J Radiat Oncol Biol Phys, 77(5): 1449-56. [Abstract] [Full-text]
93. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
    Biochem Pharmacol, 80(6): 811-8. [Abstract] [Full-text]
94. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.
    Biochem Pharmacol, 80(6): 858-66. [Abstract] [Full-text]
95. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells.
    Biochem Pharmacol, 80(6): 884-94. [Abstract] [Full-text]
96. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.
    Cancer Lett, 296(1): 106-12. [Abstract] [Full-text]
97. DiOLISTIC labeling of neurons from rodent and non-human primate brain slices.
    J Vis Exp. [Abstract] [Full-text]
98. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer.
    Cancer Sci, 101(7): 1670-7. [Abstract] [Full-text]
99. The value of pulse pressure and stroke volume variation as predictors of fluid responsiveness during open chest surgery.
    Anaesthesia, 65(7): 704-9. [Abstract] [Full-text]
100. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.
     J Acquir Immune Defic Syndr, 54(5): 524-32. [Abstract] [Full-text]
101. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts.
     J Acquir Immune Defic Syndr, 54(5): 533-41. [Abstract] [Full-text]
102. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa.
     J Acquir Immune Defic Syndr, 54(5): 489-95. [Abstract] [Full-text]
103. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1-infected patients.
     J Acquir Immune Defic Syndr, 54(5): 477-81. [Abstract] [Full-text]
104. Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy.
     J Acquir Immune Defic Syndr, 54(5): 500-5. [Abstract] [Full-text]
105. Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria.
     Crit Care Med, 38(8): 1630-6. [Abstract] [Full-text]
106. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
     Ann Hematol, 89(9): 897-904. [Abstract] [Full-text]
107. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
     Ann Hematol, 89(9): 905-12. [Abstract] [Full-text]
108. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats.
     Invest Ophthalmol Vis Sci, 51(8): 4243-52. [Abstract] [Full-text]
109. High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy.
     J Cancer Res Clin Oncol, 136(9): 1431-8. [Abstract] [Full-text]
110. Targeting and processing of site-specific DNA interstrand crosslinks.
     Environ Mol Mutagen, 51(6): 527-39. [Abstract] [Full-text]
111. Volume kinetics for infusion fluids.
     Anesthesiology, 113(2): 470-81. [Abstract] [Full-text]
112. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
     Br J Haematol, 150(3): 326-33. [Abstract] [Full-text]
113. Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.
     Pediatr Blood Cancer, 55(3): 471-7. [Abstract] [Full-text]
114. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
     Br J Haematol, 150(3): 345-51. [Abstract] [Full-text]
115. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
     Prostate, 70(11): 1166-78. [Abstract] [Full-text]
116. Immune reconstitution inflammatory syndrome due to Mycobacterium bovis Bacillus Calmette-Guerin in infants receiving highly active antiretroviral therapy: a call for universal perinatal rapid HIV testing prior to administration of BCG immunization of neonates.
     J Trop Pediatr, 56(4): 280-3. [Abstract] [Full-text]
117. Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?
     Cancer Immunol Immunother, 59(10): 1449-55. [Abstract] [Full-text]
118. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies.
     Colloids Surf B Biointerfaces, 80(2): 213-8. [Abstract] [Full-text]
119. Development of biodegradable nanoparticles for delivery of quercetin.
     Colloids Surf B Biointerfaces, 80(2): 184-92. [Abstract] [Full-text]
120. Dual-response nanocarrier based on graft copolymers with hydrazone bond linkages for improved drug delivery.
     Colloids Surf B Biointerfaces, 80(2): 145-54. [Abstract] [Full-text]
121. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.
     N Engl J Med, 363(4): 311-20. [Abstract] [Full-text]
122. A health insurance company-initiated multifaceted intervention for optimizing acid-suppressing drug prescriptions in primary care: a randomized controlled trial.
     Arch Intern Med, 170(14): 1264-8. [Abstract] [Full-text]
123. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.
     Arch Intern Med, 170(14): 1247-55. [Abstract] [Full-text]
124. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study.
     Heart, 96(16): 1291-6. [Abstract] [Full-text]
125. Repeated thrombolysis for chronologically separated ischemic strokes: a case series.
     Stroke, 41(8): 1829-32. [Abstract] [Full-text]
126. Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
     Cancer Sci, 101(8): 1846-52. [Abstract] [Full-text]
127. Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
     Cancer Sci, 101(8): 1853-60. [Abstract] [Full-text]
128. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
     Cancer Sci, 101(8): 1840-5. [Abstract] [Full-text]
129. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.
     Am J Obstet Gynecol, 203(2): 162.e1-8. [Abstract] [Full-text]
130. Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer.
     Am J Obstet Gynecol, 203(2): 160.e1-7. [Abstract] [Full-text]
131. Targeted therapy in breast cancer: current status and future directions.
     Jpn J Clin Oncol, 40(8): 711-6. [Abstract] [Full-text]
132. Vortex-assisted DNA delivery.
     Lab Chip, 10(16): 2057-61. [Abstract] [Full-text]
133. In situ mechanical characterization of mouse oocytes using a cell holding device.
     Lab Chip, 10(16): 2154-61. [Abstract] [Full-text]
134. Efficacy of posterior fixation suture augmented with talc or doxycycline.
     Graefes Arch Clin Exp Ophthalmol, 248(9): 1287-92. [Abstract] [Full-text]
135. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
     Graefes Arch Clin Exp Ophthalmol, 248(9): 1233-9. [Abstract] [Full-text]
136. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
     Eur J Haematol, 85(2): 149-57. [Abstract] [Full-text]
137. Electroporation therapy of skin cancer in the head and neck area.
     Dermatol Surg, 36(8): 1245-50. [Abstract] [Full-text]
138. Proliferative vitreoretinopathy in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
     Am J Ophthalmol, 150(2): 218-22. [Abstract] [Full-text]
139. Strategies in the design of nanoparticles for therapeutic applications.
     Nat Rev Drug Discov, 9(8): 615-27. [Abstract] [Full-text]
140. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
     J Clin Oncol, 28(22): 3611-6. [Abstract] [Full-text]
141. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
     J Clin Oncol, 28(22): 3605-10. [Abstract] [Full-text]
142. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
     J Clin Oncol, 28(22): 3623-9. [Abstract] [Full-text]
143. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
     J Clin Oncol, 28(22): 3617-22. [Abstract] [Full-text]
144. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
     J Clin Oncol, 28(22): 3644-52. [Abstract] [Full-text]
145. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
     J Clin Oncol, 28(22): 3562-9. [Abstract] [Full-text]
146. Catheter-based neurosalvage for acute embolic complication during carotid intervention.
     J Vasc Surg, 52(2): 308-13. [Abstract] [Full-text]
147. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia.
     J Vasc Surg, 52(2): 412-20. [Abstract] [Full-text]
148. Thrombolysis for acute arterial occlusion.
     J Vasc Surg, 52(2): 512-5. [Abstract] [Full-text]
149. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.
     Blood, 116(4): 593-602. [Abstract] [Full-text]
150. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.
     Blood, 116(4): 522-8. [Abstract] [Full-text]
151. Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system.
     Chem Biol Interact, 187(1): 295-8. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.